Skip to main content

Advertisement

Figure 2 | BMC Medicine

Figure 2

From: Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes

Figure 2

Cumulative incidence of all-site cancer in patients with type 2 diabetes. Stratified by drug usage and attainment of glycemic goal after adjustment for LDL-C-related risk indicators (that is, LDL-C < 2.8 mmol/L plus albuminuria or LDL-C ≥3.8 mmol/L), non-linear associations of HDL-C and triglyceride with cancer, BMI (<24, ≥27.6 kg/m2), HbA1c, (except for Figure 1a) age, sex, employment status, use of alcohol and tobacco, duration of disease, and systolic blood pressure. Additional adjustments were made for propensity scores of the drug in question and use of other medications during follow-up as appropriate. All analyses were performed after excluding prevalent drug users. Abbreviation list: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; HbA1c, glycated haemoglobin; RAS, renin-angiotensin system; TZD, thiazolidinedione.

Back to article page